VanEck Pharmaceutical ETF
PPH
75 hedge funds and large institutions have $70.5M invested in VanEck Pharmaceutical ETF in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
19% more funds holding
Funds holding: 63 → 75 (+12)
18% more capital invested
Capital invested by funds: $59.9M → $70.5M (+$10.5M)
2.25% more ownership
Funds ownership: 16.97% → 19.22% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
63% less call options, than puts
Call options by funds: $335K | Put options by funds: $909K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$6.78M |
| 2 |
LJAC
L.J. Altfest & Co
New York
|
+$2.88M |
| 3 |
SIM
Seaview Investment Managers
Miami,
Florida
|
+$1.78M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$680K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$534K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$2.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.79M |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.45M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$939K |
| 5 |
WI
Wintrust Investments
Chicago,
Illinois
|
-$882K |
PPH Hedge Fund Activity: Q1 2022 in Review
75 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2022, worth a combined $70.5M — up 18% from $59.9M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PPH positions and 7 closed out — a net gain of 14 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Phoenix Financial, opening a new position worth an estimated $6.78M. The largest seller was Clough Capital Partners, cutting an estimated $2.69M.
- 75 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2022, up from 63 in Q4 2021.
- Funds reported $70.5M of VanEck Pharmaceutical ETF stock for Q1 2022, up 18% quarter-over-quarter.
- 21 funds opened new VanEck Pharmaceutical ETF positions in Q1 2022 and 7 closed out, a net change of +14 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2022 was Phoenix Financial, an estimated $6.78M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2022 was Clough Capital Partners, an estimated $2.69M sold.
Based on aggregated 13F filings for Q1 2022.